Matches in SemOpenAlex for { <https://semopenalex.org/work/W3085859821> ?p ?o ?g. }
- W3085859821 abstract "Summary The phase 2b AMP trials are testing whether the broadly neutralizing antibody VRC01 prevents HIV-1 infection in two cohorts: women in sub-Saharan Africa, and men and transgender persons who have sex with men (MSM/TG) in the Americas and Switzerland. We used nonlinear mixed effects modeling of longitudinal serum VRC01 concentrations to characterize pharmacokinetics and predict HIV-1 neutralization coverage. We found that body weight significantly influenced clearance, and that the mean peripheral volume of distribution, steady state volume of distribution, elimination half-life, and accumulation ratio were significantly higher in MSM/TG than in women. Neutralization coverage was predicted to be higher in the first (versus second) half of a given 8-week infusion interval, and appeared to be higher in MSM/TG than in women overall. Study cohort differences in pharmacokinetics and neutralization coverage provide insights for interpreting the AMP results and for investigating how VRC01 concentration and neutralization correlate with HIV incidence." @default.
- W3085859821 created "2020-09-21" @default.
- W3085859821 creator A5000950209 @default.
- W3085859821 creator A5004112212 @default.
- W3085859821 creator A5005437196 @default.
- W3085859821 creator A5009785426 @default.
- W3085859821 creator A5016037005 @default.
- W3085859821 creator A5024262342 @default.
- W3085859821 creator A5030086016 @default.
- W3085859821 creator A5031000479 @default.
- W3085859821 creator A5036215456 @default.
- W3085859821 creator A5036401180 @default.
- W3085859821 creator A5045762100 @default.
- W3085859821 creator A5052010278 @default.
- W3085859821 creator A5055605804 @default.
- W3085859821 creator A5065306968 @default.
- W3085859821 creator A5069751295 @default.
- W3085859821 creator A5070515389 @default.
- W3085859821 creator A5071657202 @default.
- W3085859821 creator A5073260940 @default.
- W3085859821 creator A5076400272 @default.
- W3085859821 creator A5077598738 @default.
- W3085859821 creator A5085731242 @default.
- W3085859821 creator A5085762412 @default.
- W3085859821 creator A5087505554 @default.
- W3085859821 date "2020-09-03" @default.
- W3085859821 modified "2023-09-30" @default.
- W3085859821 title "Pharmacokinetics and predicted neutralization coverage of VRC01 in HIV-uninfected participants of the Antibody Mediated Prevention (AMP) trials" @default.
- W3085859821 cites W1488660595 @default.
- W3085859821 cites W1568693476 @default.
- W3085859821 cites W1874687673 @default.
- W3085859821 cites W1924338894 @default.
- W3085859821 cites W1964126023 @default.
- W3085859821 cites W1976821928 @default.
- W3085859821 cites W1992566288 @default.
- W3085859821 cites W2015237638 @default.
- W3085859821 cites W2022450888 @default.
- W3085859821 cites W2024287923 @default.
- W3085859821 cites W2087090401 @default.
- W3085859821 cites W2098013141 @default.
- W3085859821 cites W2135151522 @default.
- W3085859821 cites W2144027296 @default.
- W3085859821 cites W2159515958 @default.
- W3085859821 cites W2200798239 @default.
- W3085859821 cites W2488909960 @default.
- W3085859821 cites W2532646138 @default.
- W3085859821 cites W2571311322 @default.
- W3085859821 cites W2581209976 @default.
- W3085859821 cites W2581575342 @default.
- W3085859821 cites W2605318746 @default.
- W3085859821 cites W2728093281 @default.
- W3085859821 cites W2768623425 @default.
- W3085859821 cites W2775402122 @default.
- W3085859821 cites W2783892553 @default.
- W3085859821 cites W2883729505 @default.
- W3085859821 cites W2890429156 @default.
- W3085859821 cites W2895847356 @default.
- W3085859821 cites W2897595682 @default.
- W3085859821 cites W2901042166 @default.
- W3085859821 cites W2955777027 @default.
- W3085859821 cites W2960302558 @default.
- W3085859821 cites W2972562701 @default.
- W3085859821 cites W2982401945 @default.
- W3085859821 cites W3008033034 @default.
- W3085859821 doi "https://doi.org/10.1101/2020.09.02.20182881" @default.
- W3085859821 hasPublicationYear "2020" @default.
- W3085859821 type Work @default.
- W3085859821 sameAs 3085859821 @default.
- W3085859821 citedByCount "0" @default.
- W3085859821 crossrefType "posted-content" @default.
- W3085859821 hasAuthorship W3085859821A5000950209 @default.
- W3085859821 hasAuthorship W3085859821A5004112212 @default.
- W3085859821 hasAuthorship W3085859821A5005437196 @default.
- W3085859821 hasAuthorship W3085859821A5009785426 @default.
- W3085859821 hasAuthorship W3085859821A5016037005 @default.
- W3085859821 hasAuthorship W3085859821A5024262342 @default.
- W3085859821 hasAuthorship W3085859821A5030086016 @default.
- W3085859821 hasAuthorship W3085859821A5031000479 @default.
- W3085859821 hasAuthorship W3085859821A5036215456 @default.
- W3085859821 hasAuthorship W3085859821A5036401180 @default.
- W3085859821 hasAuthorship W3085859821A5045762100 @default.
- W3085859821 hasAuthorship W3085859821A5052010278 @default.
- W3085859821 hasAuthorship W3085859821A5055605804 @default.
- W3085859821 hasAuthorship W3085859821A5065306968 @default.
- W3085859821 hasAuthorship W3085859821A5069751295 @default.
- W3085859821 hasAuthorship W3085859821A5070515389 @default.
- W3085859821 hasAuthorship W3085859821A5071657202 @default.
- W3085859821 hasAuthorship W3085859821A5073260940 @default.
- W3085859821 hasAuthorship W3085859821A5076400272 @default.
- W3085859821 hasAuthorship W3085859821A5077598738 @default.
- W3085859821 hasAuthorship W3085859821A5085731242 @default.
- W3085859821 hasAuthorship W3085859821A5085762412 @default.
- W3085859821 hasAuthorship W3085859821A5087505554 @default.
- W3085859821 hasBestOaLocation W30858598211 @default.
- W3085859821 hasConcept C112705442 @default.
- W3085859821 hasConcept C126322002 @default.
- W3085859821 hasConcept C139254425 @default.
- W3085859821 hasConcept C14086860 @default.
- W3085859821 hasConcept C144024400 @default.
- W3085859821 hasConcept C149923435 @default.